{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:28:10Z","timestamp":1792481290091,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other therapeutic areas. An initial phase 1 study with single and multiple ascending doses of nipocalimab infused intravenously (IV) over 2\u2009h demonstrated dose-dependent serum pharmacokinetics and IgG reductions, with an adverse event (AE) profile comparable to placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The current investigation evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of nipocalimab across various IV infusion rates in a randomized, double-blind, placebo-controlled, sequential-dose study. Forty participants were randomized to receive nipocalimab 30\u2009mg\/kg over 60, 30, 15 or 7.5\u2009min (0.5, 1, 2, or 4\u2009mg\/kg\/min); nipocalimab 60\u2009mg\/kg over 15\u2009min (4\u2009mg\/kg\/min); or matching placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At doses up to 60\u2009mg\/kg and infusion rates up to 4\u2009mg\/kg\/min (maximum clinically feasible rate), single doses of nipocalimab were tolerable, with 12 (40%) participants experiencing AEs across nipocalimab cohorts compared with 1 (10%) participant in the placebo cohort. AEs deemed treatment related occurred in 6 (20%) participants receiving nipocalimab and 1 (10%) participant receiving placebo. None of the AEs were severe, and no participants discontinued treatment due to AEs. Nipocalimab provided consistent, dose-dependent serum pharmacokinetics and IgG reductions, regardless of infusion rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study supports the use of shortened durations of nipocalimab infusion for future studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2024.1302714","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:25:35Z","timestamp":1706761535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study"],"prefix":"10.3389","volume":"18","author":[{"given":"Jocelyn H.","family":"Leu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Abbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Denney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona E.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/ajcp\/27.1.52","article-title":"Effects of posture and activity on the major fractions of serum protein","volume":"27","author":"Aull","year":"1957","journal-title":"Am. J. Clin. Pathol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103016","DOI":"10.1016\/j.autrev.2021.103016","article-title":"Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases","volume":"21","author":"Chalayer","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref7","article-title":"Efficacy and safety of M281 in adults with warm autoimmune hemolytic anemia","year":""},{"key":"ref8","article-title":"A study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of M281 administered to pregnant women at high risk for early onset severe hemolytic disease of the fetus and newborn (HDFN)","year":""},{"key":"ref9","article-title":"A proof-of-concept study of the efficacy and safety of nipocalimab in participants with active rheumatoid arthritis","year":""},{"key":"ref10","article-title":"A study of nipocalimab administered to adults with generalized myasthenia gravis","year":""},{"key":"ref11","article-title":"A study of nipocalimab in adult participants with active lupus nephritis","year":""},{"key":"ref12","article-title":"A study of nipocalimab in adult participants with active systemic lupus erythematosus","year":""},{"key":"ref13","article-title":"A study of nipocalimab in adults with primary Sj\u00f6gren's syndrome (pSS)","year":""},{"key":"ref14","article-title":"Efficacy and safety study of nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)","year":""},{"key":"ref15","article-title":"A study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA)","year":""},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.2174\/138161210791164144","article-title":"Autoantibodies in autoimmune diseases","volume":"16","author":"Eggert","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/00365518009091972","article-title":"Effects of posture on concentrations of blood constituents in healthy adults: practical application of blood specimen collection procedures recommended by the Scandinavian committee on reference values","volume":"40","author":"Felding","year":"1980","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front. Immunol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11481-021-10004-9","article-title":"The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review","volume":"16","author":"Jacob","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2340\/00015555-1444","article-title":"Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus","volume":"93","author":"Kasuya","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"Kohler","year":"2011","journal-title":"J. Clin. Apher."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.htct.2022.09.022","article-title":"Selective targeting of FcRn and IgG clearance by nipocalimab preserves key immune functions","volume":"44","author":"Ling","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"key":"ref9001","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3109\/14767058.2011.633668","article-title":"Predictive factors of perinatal mortality in transfused fetuses due to maternal alloimmunization: what really matters?","volume":"25","author":"Osanan","year":"2012","journal-title":"J. Matern. Fetal. Neonatal Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.036","article-title":"Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fc\u03b3 receptors","volume":"146","author":"Shock","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1111\/trf.13913","article-title":"Plasma is a strategic resource","volume":"56","author":"Strengers","year":"2016","journal-title":"Transfusion"},{"key":"ref34","article-title":"Information about immune globulin (human) product shortage","year":"2019"},{"key":"ref35","volume-title":"VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) [package insert]","year":"2023"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1302714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:25:38Z","timestamp":1706761538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1302714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":36,"alternative-id":["10.3389\/fnins.2024.1302714"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1302714","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"article-number":"1302714"}}